Notis McConarty Edward cut its stake in Becton, Dickinson and Company (NYSE:BDX - Free Report) by 20.0% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 8,906 shares of the medical instruments supplier's stock after selling 2,230 shares during the quarter. Notis McConarty Edward's holdings in Becton, Dickinson and Company were worth $2,040,000 at the end of the most recent reporting period.
Other large investors also recently bought and sold shares of the company. Smallwood Wealth Investment Management LLC acquired a new position in shares of Becton, Dickinson and Company during the 1st quarter worth approximately $27,000. REAP Financial Group LLC raised its stake in shares of Becton, Dickinson and Company by 75.3% during the 4th quarter. REAP Financial Group LLC now owns 128 shares of the medical instruments supplier's stock worth $29,000 after buying an additional 55 shares during the period. Alpine Bank Wealth Management acquired a new position in shares of Becton, Dickinson and Company during the 1st quarter worth approximately $29,000. Cornerstone Planning Group LLC raised its stake in shares of Becton, Dickinson and Company by 341.4% during the 1st quarter. Cornerstone Planning Group LLC now owns 128 shares of the medical instruments supplier's stock worth $29,000 after buying an additional 99 shares during the period. Finally, Nexus Investment Management ULC acquired a new position in shares of Becton, Dickinson and Company during the 1st quarter worth approximately $34,000. 86.97% of the stock is owned by institutional investors and hedge funds.
Becton, Dickinson and Company Trading Up 1.0%
Becton, Dickinson and Company stock traded up $1.89 during midday trading on Friday, reaching $185.52. 1,875,850 shares of the stock traded hands, compared to its average volume of 2,931,804. The company has a 50-day simple moving average of $174.31 and a two-hundred day simple moving average of $202.75. Becton, Dickinson and Company has a 12-month low of $163.33 and a 12-month high of $251.99. The firm has a market cap of $53.17 billion, a PE ratio of 35.40, a price-to-earnings-growth ratio of 1.39 and a beta of 0.25. The company has a current ratio of 1.13, a quick ratio of 0.64 and a debt-to-equity ratio of 0.70.
Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last posted its quarterly earnings results on Thursday, May 1st. The medical instruments supplier reported $3.35 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $3.28 by $0.07. The company had revenue of $5.27 billion for the quarter, compared to analyst estimates of $5.35 billion. Becton, Dickinson and Company had a return on equity of 15.99% and a net margin of 7.28%. Becton, Dickinson and Company's revenue for the quarter was up 4.5% compared to the same quarter last year. During the same quarter last year, the company earned $3.17 EPS. Research analysts expect that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.
Becton, Dickinson and Company Dividend Announcement
The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 30th. Shareholders of record on Monday, September 8th will be given a $1.04 dividend. This represents a $4.16 dividend on an annualized basis and a yield of 2.24%. The ex-dividend date is Monday, September 8th. Becton, Dickinson and Company's dividend payout ratio is currently 79.39%.
Insider Transactions at Becton, Dickinson and Company
In other news, EVP Michael David Garrison sold 1,185 shares of the firm's stock in a transaction dated Friday, July 18th. The stock was sold at an average price of $180.29, for a total transaction of $213,643.65. Following the sale, the executive vice president owned 4,887 shares of the company's stock, valued at approximately $881,077.23. This trade represents a 19.52% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP David Shan sold 1,166 shares of the firm's stock in a transaction dated Monday, June 2nd. The stock was sold at an average price of $171.19, for a total value of $199,607.54. Following the sale, the executive vice president directly owned 4,575 shares in the company, valued at $783,194.25. This trade represents a 20.31% decrease in their position. The disclosure for this sale can be found here. 0.36% of the stock is owned by company insiders.
Wall Street Analysts Forecast Growth
BDX has been the subject of several research analyst reports. Morgan Stanley reduced their target price on Becton, Dickinson and Company from $280.00 to $196.00 and set an "overweight" rating for the company in a research note on Tuesday, May 6th. Wall Street Zen cut Becton, Dickinson and Company from a "buy" rating to a "hold" rating in a research report on Friday, May 2nd. Barclays dropped their price target on Becton, Dickinson and Company from $261.00 to $241.00 and set an "overweight" rating for the company in a research report on Tuesday, June 3rd. William Blair cut Becton, Dickinson and Company from an "outperform" rating to a "market perform" rating in a research report on Thursday, May 1st. Finally, Stifel Nicolaus dropped their price target on Becton, Dickinson and Company from $280.00 to $224.00 and set a "buy" rating for the company in a research report on Friday, May 2nd. Eight equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat, Becton, Dickinson and Company currently has a consensus rating of "Hold" and a consensus target price of $219.22.
Check Out Our Latest Research Report on Becton, Dickinson and Company
About Becton, Dickinson and Company
(
Free Report)
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.
Featured Articles
Before you consider Becton, Dickinson and Company, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Becton, Dickinson and Company wasn't on the list.
While Becton, Dickinson and Company currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
